Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

tiple myeloma: Preliminary results" (Abstract #8541).

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the la
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Regulatory and Reimbursement Landscape Poland " an essential ... in the healthcare market and provides insights into ... Most importantly, the report provides valuable insights into ...
(Date:8/28/2014)... , Aug. 28, 2014  Decision Resources Group finds that ... at around $7.7 billion by 2023 in the ... Germany , Italy , ... and Japan . The biosimilar erosion ... be balanced out by the launch of Eli Lilly,s Cyramza, ...
(Date:8/28/2014)... , Aug. 28, 2014   Edison Nation ... announced a worldwide search for product ideas to ... population.  Promising ideas uncovered through the 6-month search ... medical device manufacturers and healthcare retailers with whom ... lives of individuals age 65 and older. ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
(Date:8/29/2014)... the Fed reported an increase in industrial production ... 0.4% while manufacturing output progressed to 1.0%. , This ... February this year. Capacity use has increased by more than ... increase that could be attributed to the boost in vehicle ... a measure of slack across the industries. , Output in ...
(Date:8/29/2014)... Only a handful of CPR and basic life ... which are consistent with recent health guidelines, according ... Medicine Australasia , the journal for the Australasian ... recognition and treatment of sudden cardiac arrest are ... of Turkish emergency medicine specialists put together the ...
(Date:8/29/2014)... 2014 As a chiropractic physician and ... that there’s a direct connection between the condition of ... back. "Since conventional shoe inserts and orthotics weren’t satisfying ... my own," he said. , Customizable to a user’s ... for the foot in order to help prevent pain ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Researchers have ... in their brains. Dyslexia -- the most commonly ... problems with reading and writing. Previous research showed ... but most of those studies focused only on a ... used functional MRI to analyze how multiple brain regions ...
(Date:8/29/2014)... Angeles (PRWEB) August 29, 2014 ... Radio Today at http://www.blogtalkradio.com/dr-carol-francis/2014/08/29/psychologist-dr-carol-francis-addressing-empty-nest-syndrome .     , Mothers ... years of money, marital bliss, prodding, laughing and ... of the house this week. Relief and ... of “now what.” Dr. Carol Francis ...
Breaking Medicine News(10 mins):Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3
... MPH, an endocrinologist at Nationwide Children,s Hospital, has developed ... text messages to remind adolescent diabetes patients about their ... Dr. Dyer found an increase in overall treatment adherence ... began developing this pilot study after realizing the potential ...
... Reporter , THURSDAY, July 29 (HealthDay News) -- Although ... and ward off osteoporosis, New Zealand researchers say the supplements ... small increase in the risk for heart attack among older ... researchers suggest that people get their required calcium, if possible, ...
... CD74 is a protein that is expressed in and ... lymphocytes and antigen presenting cells. This protein is known ... immune response. Additionally, Professor Shachar,s lab has previously shown ... of the immune system, and that its stimulation by ...
... important factor, influencing both morbidity and recovery after ... allow early intervention, which may prevent later complications. ... medical evaluations to identify significant weight loss over ... thickness, serum nutritional factor levels and functional measurements ...
... (HCC) is one of the most common cancers ... of the more difficult cancers to treat. It ... A number of dietary compounds possess anti-cancer properties. ... specific targets that control cell proliferation and apoptosis. ...
... clinical medicine are familiar with learning curves, and strategies ... on clinical care. Because similar learning curves have been ... University Medical Center studied the phenomenon in the data ... point to ways to improve the quality of future ...
Cached Medicine News:Health News:Pilot study supports adolescent diabetes patients through personalized text messages 2Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 2Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 3Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 4Health News:How to detect malnutrition in patients effectively? 2Health News:Clinical trials can be improved by managing the learning curve 2Health News:Clinical trials can be improved by managing the learning curve 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: